Estetrol (medication)
Estetrol, tentative brand names Donesta and Estelle/PeriNesta, is an estrogen medication and naturally occurring steroid hormone which is under development for use as a birth control pill in combination with a progestin, in menopausal hormone therapy to treat symptoms such as vaginal atrophy, hot flashes, and bone loss, and for the treatment of breast cancer, prostate cancer, osteoarthritis, and migraine. It is taken by mouth.
Estetrol is a naturally occurring and bioidentical estrogen, or an agonist of the estrogen receptor, the biological target of estrogens like endogenous estradiol. Due to its estrogenic activity, estetrol has antigonadotropic effects and can inhibit fertility and suppress sex hormone production and levels in both women and men. Estetrol differs in various ways both from other natural estrogens like estradiol and from synthetic estrogens like ethinylestradiol, with implications for tolerability and safety. For instance, it appears to have minimal estrogenic effects in the breasts and liver. Due to its unique tissue-selective effects, estetrol has been described as a natural selective estrogen receptor modulator.
Estetrol was first discovered in 1965, and basic research continued up until 1984. It started to be studied again as well as investigated for potential medical use in 2001, and by 2008, was of major interest for possible medical use. As of 2018, estetrol is in mid- to late-stage clinical development for a variety of indications. anticipates the launch of Donesta and PeriNesta by the end of 2023.
Medical uses
Estetrol is under development for use alone for a variety of indications with the tentative brand name Donesta. Applications include hormonal contraception and menopausal hormone therapy among others. As of June 2018, it is in phase II clinical trials for pregnancy prevention and the treatment of atrophic vaginitis, vasomotor symptoms, osteoarthritis, hormonal contraception, breast cancer, and prostate cancer, while it is in phase I clinical studies for the treatment of migraine. It was also under development for the treatment of cardiovascular disorders, multiple sclerosis, and Sjögren syndrome, but development for these indications was discontinued.In addition to a single-drug formulation, estetrol is under development in combination with the progestin drospirenone for use as a birth control pill to prevent pregnancy with the tentative brand name Estelle. Drospirenone is also a potent antimineralocorticoid and antiandrogen in addition to progestogen, and in relation to this, is said to have a progesterone-like medication profile. As of April 2018, estetrol/drospirenone are in phase III clinical trials for pregnancy prevention.
Estetrol has been studied in humans at oral doses of 0.1 to 100 mg. Dosages of between 2 and 40 mg/day estetrol have been studied in postmenopausal women and found to be effective in the alleviation of menopausal symptoms.
Contraindications
General contraindications of estrogens include breast cancer, endometrial cancer, and others.Side effects
Minimal side effects have been observed with estetrol in women. In men, decreased libido and nipple tenderness have been observed with high-dose estetrol for four weeks. The medication poses a risk of endometrial hyperplasia and endometrial cancer in women similarly to other estrogens. As such, it is necessary to combine estetrol with a progestogen in women with intact uteruses to prevent such risks.Overdose
High single doses of estetrol of 100 mg have been studied in women and were found to be well-tolerated. Estetrol has been said to be only 10 to 20 times less potent orally than the highly potent estrogen ethinylestradiol. During pregnancy, estetrol levels increase to high concentrations of about 723 pg/mL on average in the mother and about 9,034 pg/mL on average in the fetus by term. Estetrol levels are 10 to 20 times higher in the fetal circulation than in the maternal circulation. The production of high amounts of estetrol during pregnancy suggests that it may be a reasonably safe compound at such concentrations.Interactions
Estetrol shows minimal to no inhibition or induction of cytochrome P450 enzymes. In addition, estetrol undergoes minimal to no metabolism, aside from conjugation. As such, estetrol is expected to harbor a low risk for drug interactions.Pharmacology
Pharmacodynamics
Estetrol is an agonist of the estrogen receptors, and hence is an estrogen. It has moderate affinity for the ERα and ERβ, with Ki values of 4.9 nM and 19 nM, respectively. As such, estetrol has 4- to 5-fold preference for the ERα over the ERβ. For comparison, the potent nonsteroidal estrogen diethylstilbestrol showed higher affinities for the ERs, with Ki values of 0.286 nM for the ERα and 0.199 nM for the ERβ. Similarly, estetrol has low affinity for the ERs relative to estradiol, and both estetrol and the related estrogen estriol require substantially higher concentrations than estradiol to produce similar effects to estradiol. The affinity of estetrol for the ERs is about 0.3% to 6.25% of that of estradiol, and its in vivo potency in animals is about 2 to 3% of that of estradiol. In women, estetrol has been found to be approximately 10 to 20 times less potent orally than ethinylestradiol, the most potent oral estrogen available. The high oral potency of estetrol in women in spite of relatively low affinity for the ERs is related to its high metabolic stability and favorable pharmacokinetics.Estetrol shows high selectivity for the ERs. It showed only 11 to 15% occupation of the androgen, progesterone, and glucocorticoid receptors at a very high concentration of 10 μM. In addition, estetrol showed no affinity for a set of 124 receptors and enzymes, with the sole exception of very weak affinity for the α1B-adrenergic receptor. Due to its high selectivity for the ERs, estetrol is anticipated to have a low risk of undesirable off-target activity and associated side effects. Furthermore, estetrol showed no inhibition of the major cytochrome P450 enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 at a very high concentration of 10 μM, unlike estradiol and ethinylestradiol. Conversely, estetrol moderately stimulated CYP3A4, while estradiol strongly stimulated CYP3A4 and ethinylestradiol moderately inhibited the enzyme. These findings suggest that estetrol has a low potential for drug interactions, including a lower potential than estradiol and particularly ethinylestradiol.
Differences from other estrogens
Estetrol has potent estrogenic effects in bone, vagina, uterus, arteries, and certain areas of the brain like the pituitary gland and hypothalamus. It has comparable efficacy to ethinylestradiol on bone turnover and hot flashes and to estradiol valerate on vaginal atrophy. In addition, estetrol has stimulatory effects on the endometrium and poses a risk of endometrial hyperplasia and endometrial cancer similarly to other estrogens. Conversely, the effects of estetrol in certain other tissues such as breast/mammary gland, liver, vascular tissue, and various brain areas differ, with weakly estrogenic or even antiestrogenic effects occurring in such tissues. Based on its mixed effects in different tissues, estetrol has been described as a unique, "natural" selective estrogen receptor modulator rather than as a "weak estrogen."Estetrol is weakly estrogenic in breast/mammary gland, but shows very low potency in this tissue and, when administered in combination with estradiol, antagonizes the effects of estradiol. Relative to estradiol, estetrol shows 100-fold lower potency in stimulation of the proliferation of human breast epithelial cells in vitro and of mouse mammary gland cells in vivo. In animal models, estetrol shows antiestrogenic effects in mammary gland tissue comparable to those of the SERM tamoxifen and of ovariectomy, antagonizing the stimulatory effects of estradiol and preventing tumor development in a 7,12-dimethylbenzanthracene mammary tumor model. As such, it is anticipated that estetrol may cause minimal proliferation of breast tissue and that it may be useful in the treatment of breast cancer.
Estetrol has relatively minimal effects on liver function. In contrast to estradiol and ethinylestradiol, estetrol does not stimulate the hepatic production of SHBG in vitro. In addition, it has been found to produce minimal changes in liver protein synthesis in women relative to ethinylestradiol, including production of sex hormone-binding globulin, corticosteroid-binding globulin, angiotensinogen, ceruloplasmin, cholesterol, triglycerides, estrogen-sensitive coagulation proteins, insulin-like growth factor 1, and insulin-like growth factor-binding proteins. In a clinical study, 10 mg/day estetrol showed only 15 to 20% of the increase of 20 μg/day ethinylestradiol on SHBG and AGT levels. For comparison, it has been reported that a dosage of estradiol that is of similar potency to ethinylestradiol in terms of suppression and hot flash relief possesses about 25% of the potency of ethinylestradiol on SHBG increase and about 35% of the potency of ethinylestradiol on AGT increase. Estetrol has shown only a minor effect on hemostatic biomarkers, including both on coagulation and fibrinolysis. Due to its minimal influence on liver function, estetrol may have a lower risk of venous thromboembolism and other undesirable side effects. This is notable, as VTE is a serious adverse effect of all known estrogens as well as synthetic SERMs. Also, oral estrogens like ethinylestradiol are associated with a reduction in lean body mass due to suppression of hepatic IGF-1 production, and this may not be expected with estetrol.
Estetrol has potent estrogenic effects in the brain in terms of relief of hot flashes, antigonadotropic effects, and ovulation inhibition. However, animal studies on the effects of estetrol on levels of allopregnanolone and β-endorphin in various brain areas have shown weak estrogenic effects when given alone and antiestrogenic effects in the presence of estradiol, suggesting that estetrol may have SERM-like effects in some regions of the brain. Estetrol has mixed effects in the vascular system similarly. It has been found to have estrogenic effects on atheroma prevention in arteries, but has antiestrogenic effects against estradiol-induced endothelial nitric oxide synthase activation and acceleration of endothelial healing.
Antigonadotropic effects
Administration of single doses of estetrol to postmenopausal women strongly suppressed secretion of luteinizing hormone and follicle-stimulating hormone, demonstrating potent antigonadotropic effects. Levels of LH were not suppressed by a dose of 0.1 or 1 mg, were slightly suppressed by a dose of 10 mg, and were profoundly suppressed by a dose of 100 mg. A profound and sustained inhibition of FSH levels, lasting up to a week, was found with a 100 mg dose of estetrol. The antigonadotropic effects of estetrol result in inhibition of ovulation and hence are involved in its hormonal contraceptive effects in women. In addition, the antigonadotropic effects of estetrol cause suppression of gonadal sex hormone production. In healthy men, 40 mg/day estetrol suppressed total testosterone levels by 60% and estradiol levels by 62% when measured by day 28 of administration. In another study of healthy men, testosterone levels were suppressed with estetrol therapy by 28% at 20 mg/day, by 60% at 40 mg/day, and by 76% at 60 mg/day after 4 weeks. Suppression of testosterone levels is the primary basis for the use of estetrol in the treatment of prostate cancer.Pharmacokinetics
Estetrol shows high oral bioavailability. Its oral bioavailability in rats was 70% relative to subcutaneous injection. The high oral bioavailability of estetrol is in contrast to estradiol, estrone, and estriol, but is more similar to ethinylestradiol. Estetrol shows a high and linear dose–response relationship across oral doses of 0.1 to 100 mg in humans, and shows low interindividual variability. Upon oral administration, estetrol is very rapidly absorbed, with maximal levels occurring within 15 to 80 minutes. At a dosage of 20 mg/day estetrol, peak levels of estetrol of 3,490 pg/mL and trough levels of 2,005 pg/mL have been reported. The high water solubility of estetrol makes it optimal for passage of the blood–brain barrier, and the drug may be expected to have effects in the central nervous system. In accordance, estetrol shows clear central effects such as alleviation of hot flashes and antigonadotropic effects in humans. In terms of plasma protein binding, estetrol is bound moderately to albumin, and is not bound to SHBG. This is in contrast to estradiol, which binds to SHBG with high affinity, but is similar to estriol and ethinylestradiol, which have only very low affinity for SHBG. Due to its lack of affinity for SHBG, the plasma distribution or availability for target tissues of estetrol is not limited or otherwise influenced by SHBG.Estetrol is metabolized slowly and minimally, and is not transformed into other estrogens such as estradiol, estrone, or estriol. This is related to the fact that estetrol is already an end-stage product of phase I estrogen metabolism in humans. The medication is conjugated via glucuronidation and to a lesser extent via sulfation. The biological half-life of estetrol is about 28 hours, with a range of 18 to 60 hours. The blood half-lives of estradiol and estriol, at about 1 to 2 hours and 20 minutes, respectively, are far shorter than that of estetrol, whereas the biological half-life of ethinylestradiol, at approximately 20 hours, is more similar to that of estetrol. Enterohepatic recirculation may occur with estetrol, similarly to other steroidal estrogens, although it has also been reported that estetrol does not seem to enter the enterohepatic circulation. Estetrol is excreted mostly or completely in urine, virtually entirely in the form of conjugates. In one study, a median of 79.7% was recovered from urine; this was primarily as estetrol glucuronide, and, to a lesser extent, as estetrol sulfate.